title: Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema.
abstract: OBJECTIVE
  To evaluate the long-term efficacy and safety of the dexamethasone intravitreal implant Ozurdex® in the treatment of diabetic macular edema (DME).
  
  
  METHODS
  This was a retrospective noncomparative study. A total of 23 patients with DME followed for at least 12 months were included. All patients were treated with at least 2 Ozurdex® injections for the treatment of DME. Best-corrected visual acuity, central retinal thickness, intraocular pressure (IOP), and cataract progression were recorded over 12 months.
  
  
  RESULTS
  From baseline, the mean decrease in central retinal thickness was 315.9 µm at the 12th month and the mean best-corrected visual acuity improvement from baseline was 8.7 letters. Ozurdex® is administered via the extended release system Novadur®. Its efficacy extends beyond 4 months with a single injection and permits allows good stabilization until the 12th month, with 2.13 injections during this period. An increase in IOP was observed in 13.1% of patients and all were managed using topical IOP-lowering medications. No glaucoma or cataract surgery was necessary, and no endophthalmitis was reported.
  
  
  CONCLUSIONS
  In real-life clinical practice, Ozurdex® has anatomical and functional effectiveness for the treatment of DME. Side effects were rare and manageable in our practice.
authors.affiliation: Ophthalmology Department, Aix Marseille Université, Hôpital Nord, Chemin des Bourrely, Marseille - France.|Institut de Neurosciences de la Timone (UMR7289), Aix Marseille Université and CNRS, Marseille - France.|P1.5 Network, Mougins - France.
authors.forename: Frederic
authors.initials: F
authors.lastname: Matonti
authors.affiliation: P1.5 Network, Mougins - France.
authors.forename: Stephan
authors.initials: S
authors.lastname: Pommier
authors.affiliation: P1.5 Network, Mougins - France.
authors.forename: Franck
authors.initials: F
authors.lastname: Meyer
authors.affiliation: P1.5 Network, Mougins - France.
authors.forename: Christian
authors.initials: C
authors.lastname: Hajjar
authors.affiliation: P1.5 Network, Mougins - France.
authors.forename: Pierre Yves
authors.initials: PY
authors.lastname: Merite
authors.affiliation: P1.5 Network, Mougins - France.
authors.forename: Eric
authors.initials: E
authors.lastname: Parrat
authors.affiliation: P1.5 Network, Mougins - France.
authors.forename: Herve
authors.initials: H
authors.lastname: Rouhette
authors.affiliation: P1.5 Network, Mougins - France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Rebollo
authors.affiliation: P1.5 Network, Mougins - France.
authors.forename: Sebastien
authors.initials: S
authors.lastname: Guigou
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D004343:Drug Implants; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007429:Intraocular Pressure; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000503:physiopathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014065:Tonometry, Ocular; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects / Q000502:physiology
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone